Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol Myers-Squibb presents follow-up data for Sprycel

Bristol Myers-Squibb presents follow-up data for Sprycel

8th December 2010

Bristol Myers-Squibb has unveiled 18-month results from the follow-up study to its phase III trial on Sprycel (dasatinib).

Results for the chronic myeloid leukaemia (CML) treatment at 18 months were consistent with the 12-month data, which demonstrated improved response rates in comparison with imatinib.

The original phase III study, entitled Dasision, found that patients treated with Sprycel achieved higher and faster rates of complete cytogenetic response and major molecular response than those who received the other drug.

Sprycel is designed for the treatment of adults with Philadelphia chromosome-positive (Ph+) chronic phase CML.

In the US, the drug is also approved for the treatment of patients with acute lymphoblastic leukaemia who have shown resistance or intolerance to prior therapy.

"The follow-up results from Dasision are important, as they continue to support the use of Sprycel as a first-line treatment option for newly-diagnosed Ph+ chronic phase CML patients," said Neil Shah of the University of California, who presented the results.

Last month, Bristol Myers-Squibb announced details of a partnership with Chinese pharmaceutical firm Simcere to develop a new oncology compound.ADNFCR-8000103-ID-800278749-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.